Cetilistat (ATL-962) Powder (282526-98-1)
Product name: Cetilistat
Other name : Cetislim
CAS:282526-98-1
MF: C25H39NO3
MW: 401.58
Assay: 99%
Appearance: White crystalline powder
Usage: Weight loss powders
Cetilistat (ATL-962) Description:
Cetislim containing the active ingredient cetilistat is considered a lipase inhibitor type of medication. The medication works by blocking the metabolization of fat within food so you do not digest it and the undigested fat will be passed through the body in bowel movement. The capsules should be used along with a low calorie, low fat diet and a proper exercise program to treat obesity. Reducing calorie intake and weight maintenance can help prevent and treat conditions such as high cholesterol, diabetes, hypertension and heart disease.
Cetilistat is a drug designed to treat obesity. It acts in the same way as the older drug orlistat by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.
Cetilistat (ATL-962) Applications:
Cetilistat is a weight loss drug used in combination with a low calorie diet. It works by blocking a substantial amount of fat from being digested and absorbed into the body. This medicine is classified as a lipase inhibitor and it works directly on the digestive system where it blocks the action of a lipolytic enzyme called lipase. These lipases are what the body uses to digest the fat.
However, when this medicine is administered alongside a meal, it binds to the lipases, thereby inhibiting them from breaking down the fat. Fats which are not hydrolyzed are instead excreted in the feces, resulting in increased fecal fat excretion and reduced fat absorption. When used together with a reduced calorie diet, it can help improve weight loss and make it easier for overweight patients to get back in shape, thereby boosting the chances of successful weight loss.
Cetilistat (ATL-962) COA:
| Items |
Specification Items |
| Appearance |
white or almost white crystalline powder,smell less |
| Melting Point |
42.0~46.0°C |
| Specific Rotation |
-31°~-39°(CHCl3,C=1) |
| Identification |
The result of HPLC is consisitent to the reference one. The result of IR is consisitent to the reference one. |
| Related Substances |
≤ 0.5% |
| Total impurity |
≤ 1.0% |
| Single impurity |
≤ 0.1% |
|
≤ 290ppm |
|
≤ 5000ppm |
| Residual on Ignition |
≤0.1% |
| Sulphate |
≤ 0.05% |
| Heavy Metal |
≤ 20ppm |
| Purity |
≤ 99.0% ~ 99.9% |
Therapeutic Approaches to Treatment of Obesity:
The growing prevalence of obesity has stimulated the search for drugs to treat this condition. Various therapeutic strategies have been explored, including:
Serotonin and noradrenaline reuptake inhibitors (anorectic agents)
Lipase inhibitors
b 3-adrenoreceptor agonists
Leptin agonists
Melanocortin-3 agonists
Endocannabinoid receptor antagonists
Cetilistat is a lipase inhibitor, with a similar mode of action to Roche’s anti-obesity medication orlistat (Xenical®) which received regulatory approval in 1997. These drugs act in the gastrointestinal tract to inhibit lipases, enzymes involved in the breakdown of dietary fats. By inhibiting the breakdown and subsequent absorption of fats from the gut, lipase inhibitors reduce fat intake and calories, thus aiding weight loss.
Rowe Chen
Sales Manager